Austria-based Themis Bioscience, backed by a consortium of VC investors, is set to list on Euronext Amsterdam on 9 November with an indicative offering price of €9.70-11.60 per share.
Fund targets companies active in the ready-to-wear, cosmetics, jewellery, accessories, health and lifestyle sectors
This is Cinven VII's third acquisition following the purchase of LGC and Thyssenkrupp Elevator
Buyer is wholly acquiring the company for a debt-free purchase price of around €13.6m
Round follows the company's €24m series-D in November 2019, also backed by Wellington and HBM